This could be confirmed by down-modulation of proliferation in human breast adenocarcinoma cells (MDA-MB231) and mouse model stage IV breast cancer cells (4T1) induced by inhibition of Rho/actin-signaling pathways [9]. This evidence concerns the gene RHO and breast cancer.